Sitravatinib
- Generic Name
- Sitravatinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C33H29F2N5O4S
- CAS Number
- 1123837-84-2
- Unique Ingredient Identifier
- CWG62Q1VTB
- Background
Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 88
- Registration Number
- NCT04904302
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Indiana University Hospital / IU Simon Cancer Center, Indianapolis, Indiana, United States
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
- Conditions
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04887194
- Locations
- 🇺🇸
Goshen Health, Goshen, Indiana, United States
🇺🇸MultiCare Health System, Tacoma, Washington, United States
🇺🇸NEXT Oncology, Fairfax, Virginia, United States
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
- Conditions
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04887870
- Locations
- 🇺🇸
Local Institution - 516-014-004, Columbus, Ohio, United States
🇺🇸Local Institution - 516-014-011, Albany, New York, United States
🇺🇸Local Institution - 516-014-027, Fairfax, Virginia, United States
A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04800614
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Dallas, Texas, United States
A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04772612
- Locations
- 🇺🇸
Texas Liver Institute, Austin, Texas, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸Nucleus Network, Saint Paul, Minnesota, United States
A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 98
- Registration Number
- NCT04734262
- Locations
- 🇨🇳
Fudan University Shanghai Cancer, Shanghai, Shanghai, China
Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT04727996
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04518046
- Locations
- 🇺🇸
MD Anderson, Houston, Texas, United States
Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 26
- Registration Number
- NCT04472650
- Locations
- 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 300
- Registration Number
- NCT04164199
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.